Literature DB >> 32563983

Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment.

Hui Ye1, Xiaojie He2, Xu Feng3.   

Abstract

It is necessary to create novel, efficacious and harmless therapeutic strategy for lung cancer treatment. The application of nanoemulsion to specifically suppress cancer progression in the tumor microenvironment would be an effective therapy. Neobavaisoflavone (Neo) is an isoflavone isolated from Psoralea corylifolia L, possesses striking anti-inflammatory and anti-cancer effects. In our stduy, Neo significantly reduced reactive oxygen species (ROS) generation in the activated myofibroblast. Furthermore, a novel Neo nanoemulsion (nano-Neo) was prepared to improve Neo solubility and bioavailability. Nano-Neo showed more effectively anti-proliferative role in lung cancer cells. In addition, in vivo analysis further demonstrated that nano-Neo could effectively suppress tumor growth compared to the free Neo-treated mice without noticeable damage to major organs. Furthermore, nano-Neo treatment markedly reduced extracellular matrix (ECM) deposition in tumor samples by repressing transforming growth factor-β (TGF-β)/SMADs signaling pathway. Meanwhile, the activated immune microenvironment in tumor tissues was dramatically improved by nano-Neo through reducing regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) infiltration, as well as improving the count of natural killer (NK) cells and M2 macrophage phenotype switch to pro-inflammatory M1. In addition, we found that the prepared nano-Neo exerted promising tumor targeting efficiency with improved pharmacokinetic properties. Therefore, the novel approach to prepare nano-Neo introduced here might provide an effective strategy for lung cancer treatment with few adverse effects.
Copyright © 2020. Published by Elsevier Masson SAS.

Entities:  

Keywords:  ECM; Immune microenvironment; Lung cancer; Nano-neobavaisoflavone; TME

Mesh:

Substances:

Year:  2020        PMID: 32563983     DOI: 10.1016/j.biopha.2020.110369

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.

Authors:  Rajeswari Raguraman; Akhil Srivastava; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-08-08       Impact factor: 15.470

Review 2.  Exosomes in the tumor microenvironment of sarcoma: from biological functions to clinical applications.

Authors:  Huali Ye; Xin Hu; Yang Wen; Chongqi Tu; Francis Hornicek; Zhenfeng Duan; Li Min
Journal:  J Nanobiotechnology       Date:  2022-09-05       Impact factor: 9.429

Review 3.  Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?

Authors:  Jiahuan Dong; Yufan Qian; Guangtao Zhang; Lu Lu; Shengan Zhang; Guang Ji; Aiguang Zhao; Hanchen Xu
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

4.  Chemosensitization of U-87 MG Glioblastoma Cells by Neobavaisoflavone towards Doxorubicin and Etoposide.

Authors:  Mateusz Maszczyk; Klaudia Banach; Marta Karkoszka; Zuzanna Rzepka; Jakub Rok; Artur Beberok; Dorota Wrześniok
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

5.  AQP9 Is a Prognostic Factor for Kidney Cancer and a Promising Indicator for M2 TAM Polarization and CD8+ T-Cell Recruitment.

Authors:  Jibo Jing; Jin Sun; Yuqing Wu; Nieke Zhang; Chunhui Liu; Saisai Chen; Wenchao Li; Cheng Hong; Bin Xu; Ming Chen
Journal:  Front Oncol       Date:  2021-11-05       Impact factor: 6.244

6.  Metabolome analysis revealed that soybean-Aspergillus oryzae interaction induced dynamic metabolic and daidzein prenylation changes.

Authors:  Haruya Takahashi; Koji Ochiai; Kuni Sasaki; Atsushi Izumi; Yu Shinyama; Shinsuke Mohri; Wataru Nomura; Huei-Fen Jheng; Teruo Kawada; Kazuo Inoue; Tsuyoshi Goto
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

Review 7.  The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

Authors:  Reem Abou Assi; Ibrahim M Abdulbaqi; Chan Siok Yee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-04

Review 8.  Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization.

Authors:  Lu Shi; Hongchen Gu
Journal:  Biomolecules       Date:  2021-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.